AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth Care
AIDS VaccinesVaccinesVaccines, SyntheticViral VaccinesVaccines, DNAVaccines, InactivatedVaccines, CombinedBacterial VaccinesVaccinationSAIDS VaccinesVaccines, ConjugateVaccines, SubunitImmunization, SecondarySimian immunodeficiency virusHIV AntibodiesMacaca mulattaAntibodies, ViralMalaria VaccinesHIV-1Antibodies, NeutralizingSimian Acquired Immunodeficiency SyndromeNeutralization TestsImmunizationMeningococcal VaccinesPapillomavirus VaccinesHepatitis B VaccinesHIV AntigensGene Products, envAcquired Immunodeficiency SyndromeAdjuvants, ImmunologicInjections, IntramuscularHaemophilus VaccinesAntibodies, BacterialHIV Envelope Protein gp120Poliovirus Vaccine, InactivatedHIV InfectionsImmunization ScheduleVaccines, AttenuatedMice, Inbred BALB CRabies VaccinesCholera VaccinesBCG VaccineDiphtheria-Tetanus-Pertussis VaccinePertussis VaccineMeasles VaccineGenetic VectorsTyphoid-Paratyphoid VaccinesTuberculosis Vaccinesenv Gene Products, Human Immunodeficiency VirusRotavirus VaccinesVaccinia virusCD8-Positive T-LymphocytesSmallpox VaccineAntibody FormationHepatitis A VaccinesChickenpox VaccineMolecular Sequence DataHIVAnthrax VaccinesVaccines, VirosomeStreptococcal VaccinesImmunoglobulin GT-Lymphocytes, CytotoxicHIV Envelope Protein gp160Gene Products, gagViral Hepatitis VaccinesImmunity, CellularCD4-Positive T-LymphocytesCross ReactionsDengue VaccinesAluminum HydroxideHemagglutination Inhibition TestsEpitopes, T-LymphocyteMeasles-Mumps-Rubella VaccinePolysorbatesAmino Acid SequenceMumps VaccineYellow Fever VaccineViral LoadT-LymphocytesInjections, IntradermalSqualeneEpitopesVaccines, Virus-Like ParticleInfluenza, HumanAntigens, BacterialTetanus ToxoidEnzyme-Linked Immunosorbent AssayAlum CompoundsAdministration, IntranasalImmunity, HumoralShigella VaccinesPoliovirus Vaccine, OralSalmonella VaccinesVaccines, AcellularDiphtheria-Tetanus VaccinePlague VaccineDiphtheria-Tetanus-acellular Pertussis VaccinesGenes, envFungal Vaccines
EfficacyVaccinationRecombinantVectorsDosesCandidatesAntibodiesImmunizationViralAntigensPlasmidInfectious DiseasesReactogenicityInduceImmune responsesProteinCOVID-19 VaccinesTypes of vaccinesVectorInfectionStrains2019PolysaccharideVirusesConjugate vaccinesImmunityRecipientsTrials10.1016AdultsEfficaciousACIPAntibody responsesProphylacticImmunogensAdenovirusHaemophilusLive vaccineAssessProtectiveClinical developmentBooster vaccineEvaluateFormulationEffectiveMRNAExperimental vaccine
Efficacy18
  • For these recommendations, ACIP considered information on vaccine efficacy (including data available since October 2009, on prevention of grade 2 or 3 anal intraepithelial neoplasia [AIN2/3], a precursor of anal cancer), vaccine safety, estimates of disease and cancer resulting from HPV, cost-effectiveness, and programmatic considerations. (cdc.gov)
  • Efficacy for prevention of HPV 6-, 11-, 16- and 18-related genital warts among males who received at least 1 vaccine dose, regardless of baseline infection or serology (intent to treat population), was 68.1% (CI = 48.8%-80.7%) ( 4 ). (cdc.gov)
  • However, its efficacy in adults remains inconsistent underlying the urgency for innovative research to develop more effective vaccines against this resilient pathogen. (nature.com)
  • Standardized assays to assess vaccine and antiviral drug efficacy are critical for the development of protective HIV-1 vaccines and drugs. (plos.org)
  • Thus far, a subtype B IMC backbone expressing Renilla luciferase (LucR), and into which the ectodomain of heterologous env coding sequences can be expressed has been successfully developed but as execution of HIV-1 vaccine efficacy trials shifts increasingly to non-subtype B epidemics (Southern African and Southeast Asia), non-subtype B HIV-1 reagents are needed to support vaccine development. (plos.org)
  • Our results suggest a possible effect of non- env HIV-1 genes on the interaction of Env and neutralizing antibodies and highlight the need to generate a library of IMCs representative of the HIV-1 subtype spectrum to be used as standardized neutralization assay reagents for assessing HIV-1 vaccine efficacy. (plos.org)
  • The dose of the vaccine varies significantly from study to study, making it very difficult to compare immune responses and vaccine efficacy. (mdpi.com)
  • To understand how complex genomic changes in these two vaccine vectors translate into antigen-specific systemic immune responses, we undertook a head-to-head vaccine immunogenicity and efficacy study in the pathogenic HIV type 1 (HIV-1) model of AIDS in Indian rhesus macaques. (nih.gov)
  • There is a need for developing optimized vaccination strategies for vulnerable groups to improve the efficacy of influenza vaccines in human. (biomedcentral.com)
  • ACIP statements on individual vaccines or immune globulins should be consulted for more details on safety and efficacy and on the epidemiology of the diseases. (cdc.gov)
  • Background The emergence of SARS-CoV-2 variants has significantly reduced the efficacy of some approved vaccines. (medrxiv.org)
  • Promising findings from our preclinical immunogenicity studies would warrant further preclinical efficacy trials in nonhuman primates, which is a critical step towards human trials. (nova.edu)
  • These new results demonstrating high sustained efficacy of the R21 malaria vaccine over a 2-year period are therefore very welcome. (sciencemediacentre.org)
  • Taken together these indicate that similar levels of vaccine efficacy may well be achievable outside the highly seasonal setting in which this particular trial was conducted. (sciencemediacentre.org)
  • Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. (canada.ca)
  • The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally. (veteransinacademia.com)
  • Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: Poliovirus vaccination. (who.int)
  • Recommendations to assure the quality, safety and efficacy of live attenuated poliomyelitis vaccine (oral). (who.int)
Vaccination17
  • Our overall goal was to improve DNA and nucleic acid vaccination technologies so that these became rapid, safe, and effective vaccine platforms for AIDS, cancer and other diseases. (cancer.gov)
  • Rapid advances in the efficiency of DNA vaccination made this approach very promising for the development of safe and effective vaccines with distinct advantages for many indications, including AIDS and cancer. (cancer.gov)
  • We used different DNA vaccine delivery procedures to discover optimal methods of DNA vaccination. (cancer.gov)
  • We compared the humoral and cellular immune responses obtained after DNA vaccination to other vaccine modalities. (cancer.gov)
  • Vaccination is a key element to PRRS control and while both inactivated and live attenuated PRRS vaccines are widely used neither provides sufficiently effective protection against the diversity of circulating PRRSV strains. (pirbright.ac.uk)
  • Vaccination history, age, health condition, and frequency of colds were important factors affecting the seroconversion rate of the influenza vaccine in human. (biomedcentral.com)
  • The results may provide supporting data for identifying influenza vaccination low responders and optimizing the vaccination strategies, thereby improving the effectiveness of the influenza vaccine in human. (biomedcentral.com)
  • My conflicts of interests are (a) being an investigator in the phase 3 R21 trial ongoing in Burkina Faso, Mali and other countries and (b) receipt by my host institution of grants from UKRI and PATH to support evaluation of seasonal vaccination with the RTS,S vaccine. (sciencemediacentre.org)
  • The vaccine was safe and well tolerated, induced potent serum IgG & IgA responses waning post last vaccination, and low and intermittent mucosal IgG, but did not induce neutralizing activity neither in serum nor vaginal samples. (europa.eu)
  • These data -- sorry, these patients, when they go for their COVID-19 or their SARS-CoV-2 test, they do self-report a vaccine history at the time of registration, and we exclude from the study anybody who does not report a vaccination status. (cdc.gov)
  • However, vaccination with LPS was significantly associated with lower weight loss post-bacterial challenge independent of co-administration with adenoviral vaccine constructs, supporting further vaccine development based on LPS. (ox.ac.uk)
  • Live, attenuated vaccines should be administered only when an inactivated version does not exist and the risk of the disease clearly outweighs the theoretical risk of vaccination. (hivguidelines.org)
  • Use live, attenuated vaccines only if an inactivated alternative is not available and the risk of disease is greater than the risk of vaccination. (hivguidelines.org)
  • We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. (plos.org)
  • The study was amended to evaluate safety and immunogenicity of a booster vaccination with Ad26.ZEBOV, administered approximately 1 year after the first vaccination, in healthy adults. (plos.org)
  • We conducted a randomised trial to assess the safety and the immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in 3 different vaccination intervals in healthy and HIV-infected adults. (plos.org)
  • But it can also mean the same thing as vaccination, which is getting a vaccine to become protected against a disease. (medlineplus.gov)
Recombinant11
  • Recombinant subunit protein vaccines use larger pieces of proteins from HIV. (healthline.com)
  • A novel recombinant protein vaccine for human schistosomiasis caused by Schistosoma mansoni is under development in our laboratories. (bcm.edu)
  • The Sm -TSP-2 schistosomiasis vaccine is comprised of a 9 kDa recombinant protein corresponding to the extracellular domain of a unique S. mansoni tetraspanin. (bcm.edu)
  • We are evaluating a range of recombinant vaccine candidates, based on protein subunits as well as viral and mRNA vectors. (pirbright.ac.uk)
  • Recombinant adenovirus type 5 (rAd) has been used as a vaccine platform against many infectious diseases and has been shown to be an effective vaccine vector. (mdpi.com)
  • Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. (ox.ac.uk)
  • We have generated a stable recombinant S. mitis expressing a HIV/SIV and we found that oral delivery of this vaccine vector was safe and in a heterologous rSmitis prime attenuated viral vector/Env protein induced robust mucosal and systemic cytotoxic T cell (CTL) response and neutralizing antibody response. (nova.edu)
  • The central hypothesis is that our heterologous prime-boost strategy will induce high magnitude and durable mucosal and systemic CTLs and neutralizing antibodies against HIV-1.The Specific Aims of this project are: 1) Conduct preclinical immunogenicity assessment of rSmitis prime- recombinant MVA vector and Env protein boost strategy in small laboratory animals. (nova.edu)
  • 3) Conduct preclinical immunogenicity assessment of rSmitis prime- recombinant MVA vector and Env protein boost strategy in non-human primates. (nova.edu)
  • Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. (emmes.com)
  • Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine. (emmes.com)
Vectors9
  • Thus, replication-competent NYVAC-C-KC vectors acquired relevant immunological properties as vaccine candidates against HIV/AIDS, and the viral B19 molecule exerts some control of immune functions. (uni-regensburg.de)
  • Instead of the classical types of vaccines such as live and inactivated viruses, several novel immunogens including protein subunit and DNA vaccines as well as viral and bacterial vectors are currently being examined. (aerzteblatt.de)
  • Recent applications of SeV-based vectors include the reprogramming of somatic cells into induced pluripotent stem cells and vaccine creation. (wikipedia.org)
  • The methods (RNA or codon optimization to increase mRNA stability transport and expression) had applications in both DNA and viral vaccine vectors and also in gene therapy protocols. (cancer.gov)
  • These studies were important in understanding the strengths and weaknesses of different vectors and protocols and provided guidance for further development of improved vaccine protocols. (cancer.gov)
  • We are also exploring the potential for live attenuated PRRSV and pseudorabies virus to act as vaccine vectors for Nipah and thus provide a bivalent vaccine. (pirbright.ac.uk)
  • Poxvirus vectors have proven to be highly effective for boosting immune responses in diverse vaccine settings. (nih.gov)
  • mitis vaccine vectors by performing extensive immunogenicity studies, preclinical safety assessments and determine bacterial factors that impact immunogenicity with the goal of refining the vaccine vector. (nova.edu)
  • The Thai RV144 human trial and current preclinical studies show that the most promising vaccine strategies may involve combining various vaccine delivery systems with different immunogenic properties in a heterologous prime- boost strategy that utilizes HIV/SIV envelope protein immunogens and pox or adenoviral vectors. (nova.edu)
Doses12
  • Before 2021, ACIP recommended 23-valent pneumococcal polysaccharide vaccine (PPSV23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in combination with 1-3 doses of PPSV23 in series (PCV13 followed by PPSV23), for use in U.S. adults depending on age and underlying risk for pneumococcal disease. (cdc.gov)
  • In addition, ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. (cdc.gov)
  • When immunized IM, mice had substantially higher antibody responses at the higher vaccine doses, whereas, the IN immunized mice showed a lower response to the higher rAd vaccine doses. (mdpi.com)
  • Rats did not show dose-dependent antibody responses to increasing vaccine doses. (mdpi.com)
  • reports over 70% protection against clinical episodes of malaria in Burkinabe children over a two-year period following three priming doses of the R21 malaria vaccine, given in early life, followed by a booster dose of vaccine given just prior to the malaria transmission season, an important finding. (sciencemediacentre.org)
  • The trial did not include a group of children who received just the priming doses of vaccine, so it is not possible to deduce from this paper how necessary booster doses of the R21 vaccine are to sustain protection over the first five or more years of life during which children are still at high risk of malaria in many seasonal transmission areas. (sciencemediacentre.org)
  • However, the marked decline in anti-CSP antibody titre in the months after priming, as seen with the RTS,S/AS01 vaccine, and the evidence presented in this and other studies that anti-CSP antibody titre is associated with protection, suggests that booster doses are likely to be needed to sustain protection. (sciencemediacentre.org)
  • The volunteers will receive two doses of a DNA vaccine candidate followed by two doses of a modified vaccinia Ankara (MVA) candidate over two months. (vaxreport.org)
  • Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. (geneticimmunity.ru)
  • Immunogenicity, vaccine response monitoring, and requirements for additional booster doses for patients with HIV are discussed on pages for individual vaccines. (hivguidelines.org)
  • This Phase II study was part of this accelerated program, evaluating the safety and immunogenicity of the 2-dose vaccine regimen in healthy and HIV-infected African adults, with 28-, 56-, and 84-day intervals between doses. (plos.org)
  • It includes who should get the vaccines, how many doses they need, and when they should get them. (medlineplus.gov)
Candidates13
  • After 30 years of working on AIDS research, an American lab has developed new vaccine candidates that appear promising enough to consider advancing into clinical trials within the next two years. (sciencedaily.com)
  • His lab has developed new vaccine candidates that he said are promising enough to consider advancing into clinical trials within the next two years. (sciencedaily.com)
  • Here we developed novel replicating poxvirus NYVACbased HIV/AIDS vaccine candidates expressing clade C HIV-1 antigens, with one of them lacking the vaccinia virus B19 protein, an inhibitor of the type I interferon response. (uni-regensburg.de)
  • Several vaccine candidates are currently undergoing clinical evaluation. (aerzteblatt.de)
  • And to support the development of COVID-19 vaccine candidates by utilising the pig as a preclinical model to study vaccine immunogenicity. (pirbright.ac.uk)
  • We are supporting the UK response to the COVID-19 pandemic by evaluating a range of vaccine candidates for immunogenicity in pigs to inform further clinical development. (pirbright.ac.uk)
  • Recent reports reveal marked differences in the gene expression of human dendritic cells infected with two leading poxvirus-based human immunodeficiency virus (HIV) vaccine candidates, New York vaccinia virus (NYVAC) and modified vaccinia virus Ankara (MVA). (nih.gov)
  • The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. (ox.ac.uk)
  • GeoVax, a US-based biotechnology company, recently began enrolling volunteers for a Phase I trial to evaluate the safety and immunogenicity of the company's AIDS vaccine candidates at four sites in the US. (vaxreport.org)
  • The vaccine candidates were developed by Harriet Robinson at Emory University's Yerkes National Primate Research Center in Atlanta and neither can cause HIV infection. (vaxreport.org)
  • Fifty-one vaccine candidates were designed mainly to mimic fusion intermediate conformations of gp41 and in some instance to increase exposure of the 2F5/4E10 epitopes. (europa.eu)
  • Immuno Cure focuses on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented "PD-1-enhanced DNA Vaccine Platform" and "Anti-Δ42PD1 Antibody Platform" with two DNA vaccine candidates, ICVAX and ICCOV, currently in clinical trials. (media-outreach.vn)
  • with two DNA vaccine candidates currently in clinical trials. (media-outreach.vn)
Antibodies10
  • Researchers believe that for an AIDS vaccine to be effective, it must stimulate the immune system to make "broadly neutralizing antibodies" that are effective against multiple strains of the virus. (sciencedaily.com)
  • One key to improving the vaccine, Berman said, came from independent lines of investigation pointing to the importance of antibodies that recognize a specific segment of gp120 known as the V1/V2 domain. (sciencedaily.com)
  • We found that the vaccine that gave partial protection in the RV 144 trial had very little of the kind of carbohydrate required to bind these antibodies. (sciencedaily.com)
  • Current pneumococcal vaccines use the pneumococcal capsular polysaccharides as antigens to generate serotype-specific antibodies, which facilitate serotype-specific clearance of pneumococci through opsonophagocytosis ( 4 ). (cdc.gov)
  • These antibodies will then be used to identify highly conserved vaccine targets that may be engineered to induce cross-protection. (pirbright.ac.uk)
  • The overall objective of EuroNeut-41 was to design a vaccine that raises antibodies able to prevent HIV cell fusion by blocking the virus fusion protein gp41 in its pre-fusogenic conformation. (europa.eu)
  • Headquartered at Fred Hutch, the HIV Vaccine Trials Network (HVTN) is the world's largest publicly funded multi-disciplinary international collaboration facilitating the development of vaccines and antibodies to prevent HIV/AIDS. (veteransinacademia.com)
  • Antibodies elicited by purified C. burnetii lipopolysaccharide (LPS) correlate with protection against Q fever, while antigens encoded by adenoviral vectored vaccines can induce cellular immune responses which aid clearing of intracellular pathogens. (ox.ac.uk)
  • Led by the AEF Greater Bay Area Fund that Gobi Partners GBA (" Gobi GBA ") manages, this round will be used to accelerate the development of DNA vaccines and antibodies, as well as to prepare for an initial public offering (" IPO ") in Hong Kong. (media-outreach.vn)
  • Immuno Cure will continue to be at the frontier of DNA medicines, antibodies and innovative immunotherapies, conducting R&D on novel and effective vaccine technologies to enhance our arsenal against cancers and infectious diseases. (media-outreach.vn)
Immunization6
  • The NIAID requires a Primate Core Immunology Laboratory to assay specimens from macaques, chimpanzees, or other primates for humoral and cellular immune responses induced by immunization with prototype Simian Immunodeficiency Virus (SIV) and Human Immunodeficiency Virus (HIV) vaccines. (nih.gov)
  • This report compiles and summarizes all published recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. (cdc.gov)
  • Other organizations, particularly the Expanded Programme on Immunization of the World Health Organization, have made different recommendations, particularly with respect to the use of oral polio vaccine (OPV) and Bacille Calmette-Guerin (BCG) for immunocompromised persons. (cdc.gov)
  • This document, the "Advisory Committee Statement: Canadian Immunization Guide Chapter on Influenza and National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2020-2021", updates NACI's recommendations regarding the use of seasonal influenza vaccines. (canada.ca)
  • This compendium of immunization recommendations for adults (≥18 years) with HIV was compiled by the New York State Department of Health AIDS Institute (NYSDOH AI) to assist clinical practitioners in New York State who provide primary care to adults with HIV. (hivguidelines.org)
  • A vaccine, or immunization, schedule lists which vaccines are recommended for different groups of people. (medlineplus.gov)
Viral8
  • Even if vaccines do not prevent infection, a vaccine strategy that reduces the viral load and thus transmission and slows down the disease process would be epidemiologically useful and probably feasible. (aerzteblatt.de)
  • Researchers hope a therapeutic HIV vaccine could reduce a person's viral load . (healthline.com)
  • Viral vector-based vaccines offer the potential to provide protection against virulent pathogens entering via the mucosal route. (pirbright.ac.uk)
  • Standard vaccines work similarly but use a dead or weak virus as their base, forgoing the process of constructing viral proteins from scratch. (livescience.com)
  • A current goal of vaccine development against human immunodeficiency virus (HIV) is to develop a strategy that stimulates long-lasting memory T-cell responses, and provides immediate cytotoxicity in response to viral challenge. (elsevierpure.com)
  • ICVAX, a therapeutic DNA vaccine candidate against HIV/AIDS, was developed with an aim to induce broadly reactive polyfunctional viral-specific T cells to achieve functional cure in HIV/AIDS. (media-outreach.vn)
  • Viral vector vaccines use genetic material, which gives your cells instructions for making a protein of the germ. (medlineplus.gov)
  • New combination vaccines should induce similar or superior levels of neutralizing antibody in serum for individual protection against paralytic disease and mucosal immunity that effectively decreases viral replication in the intestine and pharynx for population protection against transmission of poliovirus. (who.int)
Antigens5
  • The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in phase I clinical trials. (uni-regensburg.de)
  • We have therefore identified and characterised conserved T cell antigens from PRRSV and are evaluating their vaccine potential using a novel vaccine vector platform based on an attenuated herpesvirus. (pirbright.ac.uk)
  • The project has been structured in 3 main pathways or "tracks": a Discovery track, aiming at designing gp41-based antigens (Ag) using an iterative improvement process, and two development tracks (Parenteral and Mucosal) to determine the safety and immunogenicity of the Ags and the optimal administration conditions before selecting the most promising candidate for clinical development. (europa.eu)
  • Potential Q fever vaccine antigens include lipopolysaccharide (LPS) and several C. burnetii surface proteins. (ox.ac.uk)
  • Multiple vaccine constructs encoding single or fusion antigens from C. burnetii were synthesised. (ox.ac.uk)
Plasmid3
  • Previously, we showed that DNA vaccine expression in the tissues is a major limiting step for meaningful immunogenicity and we developed general methods for efficient plasmid expression. (cancer.gov)
  • We developed a candidate DNA vaccine called "DNA-4"consisting of 4 plasmid DNAs encoding Nef, Gag, Pol(rt), and gp140 HIV-1 proteins. (mdpi.com)
  • This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine. (emmes.com)
Infectious Diseases3
  • These advancements formed the basis for the accelerated development of DNA vaccines for AIDS, other infectious diseases and also cancer. (cancer.gov)
  • In this context, these new approaches include skipping over some animal testing, although virologists at the National Institute of Allergy and Infectious Diseases did give the experimental vaccine to lab mice on the same day that the human trial began recruiting participants, according to Stat News. (livescience.com)
  • Results of the phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21, in African children have been published in the Lancet Infectious Diseases . (sciencemediacentre.org)
Reactogenicity2
  • Conclusions A fourth dose of NVX-CoV2373 enhanced immunogenicity without increasing reactogenicity. (medrxiv.org)
  • The vaccine was well tolerated but was associated with more reactogenicity at the highest dose. (emmes.com)
Induce3
  • IMPORTANCE It is of special importance to find a safe and effective HIV/AIDS vaccine that can induce strong and broad T cell and humoral immune responses correlating with HIV-1 protection. (uni-regensburg.de)
  • HIV vaccine to induce cytotoxic T cells recognizing conserved HIV-1/2-epitopes derived from the most frequent HLA types of the human population. (geneticimmunity.ru)
  • The worldwide distribution of Q fever suggests a need for vaccines that are more efficacious, affordable, and does not induce severe adverse reactions in vaccine recipients with pre-existing immunity against Q fever. (ox.ac.uk)
Immune responses6
  • By dissecting the pathological and protective immune responses evoked by PRRSV, we will be able to design safer and more effective vaccines. (pirbright.ac.uk)
  • A final vaccine analysis using a lethal influenza virus challenge showed that despite the differences in the immune responses observed in the mice, the mice had very similar patterns of protection. (mdpi.com)
  • Differences in the immune responses in outbred animals were not distinguished by enzyme-linked immunospot assays, but differences were distinguished by multiparameter fluorescence-activated cell sorter analysis, revealing a difference between the number of animals with both CD4(+) and CD8(+) T-cell responses to vaccine inserts (MVA) and those that elicit a dominant CD4(+) T-cell response (NYVAC). (nih.gov)
  • At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. (ox.ac.uk)
  • 2) Determine the role of bacterial factors on anti-HIV/SIV mucosal immune responses with the goal of fine-tuning vector immunogenicity. (nova.edu)
  • The timing of ART initiation generally did not affect immune responses to vaccines between HIV-infected groups. (smu.ac.za)
Protein3
  • The AIDSVAX vaccine was based on the gp120 envelope protein. (sciencedaily.com)
  • Therefore, we will develop a heterologous rSmitis-prime rMVA and Env protein boost vaccine strategy. (nova.edu)
  • mRNA vaccines use messenger RNA, which gives your cells instructions for how to make a protein (or piece of a protein) of the germ. (medlineplus.gov)
COVID-19 Vaccines6
  • I'd like to welcome you to today's COCA call, COVID-19 Update: Clinical Guidance and Patient Education for Bivalent COVID-19 Vaccines. (cdc.gov)
  • Discuss current data on effectiveness of COVID-19 vaccines. (cdc.gov)
  • Review current recommendations for bivalent COVID-19 vaccines. (cdc.gov)
  • With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world's leading cancer, infectious disease and biomedical research centers. (veteransinacademia.com)
  • Certara, the global leader in the biosimulation announced its plan in 2020 to develop a new biosimulation platform for Covid-19 vaccines and major enhancement in its immunogenicity and immune-oncology QRS platform. (knowledge-sourcing.com)
  • The US Centers for Disease Control and Prevention previously issued interim clinical considerations stating that 'COVID-19 vaccines and other vaccines, including influenza vaccines , can be administered without regard to timing. (flutalk.net)
Types of vaccines2
Vector5
  • SeV has several features that are important in a vector for a successful vaccine: the virus does not integrate into the host genome, it does not undergo genetic recombination, it replicates only in the cytoplasm without DNA intermediates or a nuclear phase and it is does not cause any disease in humans or domestic animals. (wikipedia.org)
  • Live vector vaccines use non-HIV viruses to carry HIV genes into the body to trigger an immune response. (healthline.com)
  • We will develop Streptococcus mitis, as a potential vaccine vector for the induction of protective mucosal immunity against HIV. (nova.edu)
  • S. mitis has important features that makes it an attractive mucosal vaccine vector. (nova.edu)
  • A second trial began recently in Zambia to evaluate the safety and immunogenicity of an AIDS vaccine candidate that uses an adeno-associated virus (AAV) vector to deliver pieces of HIV's genetic material to the immune system. (vaxreport.org)
Infection10
  • The latest results from this effort have Berman sounding optimistic about the prospects for a vaccine that can be effective in protecting against HIV infection. (sciencedaily.com)
  • Although the effect was small, RV 144 is still the only clinical trial in which a vaccine has shown any protective effect at all against HIV infection. (sciencedaily.com)
  • Thus far, there is no experimental or clinical evidence that any vaccine will be able to completely prevent HIV infection. (aerzteblatt.de)
  • In one of the study from our laboratory, we have shown that a DNA vaccine expressing α-crystallin provides considerable protection to guinea pigs against M. tuberculosis infection 12 . (nature.com)
  • We aimed to improve DNA vaccine platform technology and develop immunogens able to prevent HIV infection or progression to AIDS. (cancer.gov)
  • HIV is an infection until it progresses to stage 3, or AIDS . (healthline.com)
  • With most infections, vaccines buy the body more time to clear the infection on its own before disease occurs. (healthline.com)
  • This means there's more chance for infection that a vaccine can't prevent. (healthline.com)
  • If even these preliminary animal experiments appear harmful or don't prevent infection, the conductors of the clinical trial should be prepared to stop testing the vaccine in humans, Karen Maschke, a scholar in bioethics at the Hastings Center and the editor of the journal Ethics & Human Research, told Stat News. (livescience.com)
  • CDC has developed clinical considerations for prevention and treatment of monkeypox in persons with HIV infection, including pre-exposure and postexposure prophylaxis with JYNNEOS vaccine, treatment with tecovirimat, and infection control. (cdc.gov)
Strains5
  • Identifying the key determinants of PRRSV proteins that mediate immune evasion or contribute to disease to provide rational targets for the production of attenuated vaccine strains. (pirbright.ac.uk)
  • 4 ] However, such protection effectiveness may be lower for some reasons, especially when the vaccine strains are mismatched with circulating viruses. (biomedcentral.com)
  • History of Sabin attenuated poliovirus oral live vaccine strains. (who.int)
  • The ful data concerning the history of attenuated poliovirus strains developed by one of us (Sabin, 1965) for vaccine production do not appear in a single journal. (who.int)
  • Over the past few years we have had frequent requests for the details such as isolation and attenuation and accordingly we felt that bringing the data together in the report below would be both helpful and informative to those involved in the production and control of poliovirus vaccine (oral) prepared from these strains. (who.int)
20191
  • During 2018-2019, approximately 60%-75% of all IPD in adults was caused by the 24 pneumococcal serotypes that were included in the formulations of commercially available polysaccharide conjugate vaccine (PCV) or pneumococcal polysaccharide vaccine (PPSV) vaccines (i.e. (cdc.gov)
Polysaccharide1
  • For specific immunocompromising conditions (e.g., asplenia), such patients may be at higher risk for certain diseases, and additional vaccines, particularly bacterial polysaccharide vaccines {Haemophilus influenzae type b (Hib), pneumococcal and meningococcal}, are recommended for them. (cdc.gov)
Viruses7
  • Sendai virus is used as a backbone for vaccine development against Mycobacterium tuberculosis that causes tuberculosis, against HIV-1 that causes AIDS and against other viruses, including those that cause severe respiratory infections in children. (wikipedia.org)
  • It's so hard to develop a vaccine for HIV because it's different from other types of viruses. (healthline.com)
  • Most vaccines are made with killed or weakened viruses. (healthline.com)
  • In addition, we are applying our expertise in porcine immunology and vaccinology to contribute to the development of vaccines to combat new and emerging zoonotic viruses, such as the Nipah virus and SARS-CoV-2. (pirbright.ac.uk)
  • 2 ] The risk of seeking treatment will decrease by 40-60% if influenza vaccine viruses match circulating viruses. (biomedcentral.com)
  • Furthermore, we described the versatility of plant viruses, with innate immunostimulatory properties, in providing a huge natural resource of carriers that can be used to develop the next generation of sustainable vaccines. (eurekaselect.com)
  • For many years, flu vaccines were designed to protect against three different flu viruses: an influenza A virus, an influenza A virus and one influenza B virus, even though there are two different lineages of B viruses that circulate during most seasons. (flutalk.net)
Conjugate vaccines1
  • In 2021, two new pneumococcal conjugate vaccines (PCVs), a 15-valent and a 20-valent PCV (PCV15 and PCV20), were licensed for use in U.S. adults aged ≥18 years by the Food and Drug Administration. (cdc.gov)
Immunity8
  • The strong and effective cellular immunity achieved by optimized DNA is also an important consideration for the expanding field of cancer vaccines. (cancer.gov)
  • We have a longstanding interest in understanding immunological mechanisms underlying protective immunity and the application of this knowledge to the development of new or improved vaccines. (pirbright.ac.uk)
  • Vaccine strategies that elicit robust mucosal immunity may potentially be effective in preventing mucosal transmission of HIV and other pathogens. (nova.edu)
  • This vaccine strategy may facilitate the generation of an efficacious vaccine for HIV, and other chronic diseases that require enhanced cell-mediated immunity, including HCV and metastatic cancer. (elsevierpure.com)
  • The adenoviral vectored vaccine constructs alone elicited strong cellular immunity, but this response was not correlative with protection in mice. (ox.ac.uk)
  • So getting immunity from a vaccine is safer than getting immunity by being sick with the disease. (medlineplus.gov)
  • Community immunity, or herd immunity, is the idea that vaccines can help keep communities healthy. (medlineplus.gov)
  • Community immunity is especially important for people who can't get certain vaccines. (medlineplus.gov)
Recipients4
  • NACI continues to recommend that, in the absence of contraindications, HCWs and other care providers in facilities and community settings should be vaccinated annually against influenza, and recommends the inclusion of this group among the particularly recommended recipients of influenza vaccine. (canada.ca)
  • At week 4, vaccine antigen-specific T cell responses were detected in 28 (93.3%) and 18 (60%) of 30 vaccine recipients for CD4(+) and CD8(+) T cells, respectively, by intracellular cytokine staining assay and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay. (emmes.com)
  • Env-specific antibody responses were detected in 15 (50%) of 30 vaccine recipients by enzyme-linked immunosorbant assay and in 28 (93.3%) of 30 vaccine recipients by immunoprecipitation followed by Western blotting. (emmes.com)
  • A single injection induced HIV-1 antigen-specific CD4(+) T cell, CD8(+) T cell, and antibody responses in the majority of vaccine recipients. (emmes.com)
Trials8
  • and (5) maintaining test result database and transferring data to the AIDS Vaccine Clinical Trials Network (AVCTN) Data Coordinating and Analysis Center (DCAC). (nih.gov)
  • Despite many trials of possible vaccines, though, a truly effective vaccine is still not available. (healthline.com)
  • The vaccine candidate, tgAAC09, was developed by US-based biotechnology company Targeted Genetics and was tested at a lower dose in Phase I trials in Belgium, Germany, and India. (vaxreport.org)
  • To date, the Network has conducted the majority of the published, presented, or ongoing clinical trials of preventive HIV vaccines worldwide. (veteransinacademia.com)
  • Although vaccines are a key biomedical prevention tool, resource limited settings often lack the infrastructure , regulatory frameworks , and skilled human resource to conduct vaccine clinical trials. (bvsalud.org)
  • conducting phase I-III vaccine trials and contribution to national ethical and regulatory frameworks that protect participants. (bvsalud.org)
  • As of 2022, MUWRP had successfully conducted and completed five phase I/II HIV vaccine clinical trials, five for Ebola and Marburg, while one phase I/II Schistosomiasis and one phase III COVID-19 vaccine clinical trial are ongoing. (bvsalud.org)
  • The completed vaccine trials provided critical scientific knowledge on the safety and immunogenicity of investigational products which informed the design of better vaccines for diseases of global health importance. (bvsalud.org)
10.10161
Adults5
  • Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23. (cdc.gov)
  • PPSV23 (Pneumovax23) is a 23-valent vaccine that has been recommended for use since the 1980s for persons aged ≥2 years with certain underlying medical conditions and for adults aged ≥65 years ( Table 1 ) (Figure). (cdc.gov)
  • Flucelvax® Quad is a mammalian cell culture-based, inactivated seasonal influenza vaccine that has recently been authorized for use in Canada in adults and children ≥9 years of age. (canada.ca)
  • In Study 3 , 565 adults 18 years of age and older who had received one dose of Fluzone Quadrivalent, TIV-1, or TIV-2 were included in the per-protocol immunogenicity analysis. (flutalk.net)
  • It's important for both children and adults to get their vaccines according to the schedule. (medlineplus.gov)
Efficacious2
  • There is therefore an urgent need to develop more efficacious vaccines to aid PRRSV control. (pirbright.ac.uk)
  • We also aim to develop a safe and efficacious Nipah virus vaccine for pigs that will aid the prevention and control of Nipah outbreaks. (pirbright.ac.uk)
ACIP1
  • ACIP recommends either vaccine for routine use in females aged 11 or 12 years ( 3 ). (cdc.gov)
Antibody responses1
  • We studied the effect of maternal HIV-exposure and timing of antiretroviral treatment (ART) in HIV-infected infants on antibody responses to combined diphtheria-toxoid-tetanus-toxoid-whole cell pertussis and Haemophilus influenzae type b conjugate vaccine (HibCV) and monovalent hepatitis B vaccine (HBV). (smu.ac.za)
Prophylactic5
  • We developed and tested new technologies including nucleic acid delivery methods in vivo , prophylactic and therapeutic vaccines and immunotherapies. (cancer.gov)
  • Most vaccines are prophylactic, which means they prevent a person from getting a disease. (healthline.com)
  • This would make it a prophylactic vaccine. (healthline.com)
  • Possible vaccines are being explored for both prophylactic and therapeutic uses. (healthline.com)
  • With Ebola outbreaks increasing, there is an unmet medical need for a prophylactic vaccine to prevent and mitigate Ebola outbreaks. (plos.org)
Immunogens1
  • It is a commensal nonpathogenic bacterium in pediatric and adult populations and it is genetically tractable for expression of vaccine immunogens. (nova.edu)
Adenovirus1
  • Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines. (ox.ac.uk)
Haemophilus1
Live vaccine1
  • For patients with HIV and CD4 counts ≥200 cells/mm 3 , inactivated forms of vaccines such as those for polio, influenza, typhoid, and zoster are preferred over the live vaccine options. (hivguidelines.org)
Assess1
  • In parallel, a questionnaire was submitted to a population of women in Haiti to assess their willingness to participate in a future HIV vaccine trial. (europa.eu)
Protective1
  • Nevertheless, there was no difference in proportion of HUU and HIV-infected infants who developed sero-protective vaccine-specific antibody levels postvaccination. (smu.ac.za)
Clinical development2
  • Prior to this, Dr. Chirmule has held leadership positions in Amgen (Thousand Oaks, CA) and Merck Vaccines (West Point, PA) has contributed to clinical development of vaccines and biopharmaceuticals. (prlog.org)
  • To address the urgent medical need during the 2014 to 2016 outbreak, the clinical development of the 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo was accelerated. (plos.org)
Booster vaccine2
  • acr ) was generated which was further evaluated for its ability to impart protection as a booster vaccine against tuberculosis in a heterologous prime boost approach. (nature.com)
  • ICCOV, a preventive COVID-19 DNA vaccine candidate, has entered the Phase IIa clinical trial in Hong Kong, which is designed as an open-label study to evaluate the immunogenicity and safety of ICCOV as a booster vaccine in a total of 60 healthy adult volunteers between 18 and 75 years of age. (media-outreach.vn)
Evaluate2
  • was conducted in UK to evaluate the safety and immunogenicity of EN41-UGR7C in Alum (3 IM injections, 3 months of F-U) in 24 healthy female volunteers. (europa.eu)
  • The Phase I clinical trial of ICVAX, which is underway in Shenzhen, is designed as a randomized, double-blinded, placebo-controlled study to evaluate the safety and immunogenicity of ICVAX in a total of 45 stable HIV/AIDS patient volunteers under antiretroviral therapy. (media-outreach.vn)
Formulation2
  • We enrolled volunteers who were: (1) Han Chinese, (2) and had not already received the northern hemisphere formulation of influenza vaccine for the corresponding year. (biomedcentral.com)
  • Interference among the three attenuated poliovirus serotypes was minimized with a 'balanced- formulation' vaccine, and serologic responses after IPV were optimized by adjusting the antigenic content of each inactivated poliovirus serotype. (who.int)
Effective7
  • This trial (known as RV 144) showed that the combined vaccine was safe and 31 percent effective in preventing new HIV infections. (sciencedaily.com)
  • However, the unsatisfactory performance of BCG in controlling the adult pulmonary tuberculosis has made the development of an effective vaccine against M. tuberculosis a prime objective of the TB research. (nature.com)
  • The lengthy process requires that scientists first give the vaccine to animals to determine whether it's safe and effective at preventing the disease in question. (livescience.com)
  • For many years before the development of effective antiretroviral therapy (ART), these infections inflicted significant morbidity and mortality on patients living with AIDS. (medscape.com)
  • [ 4 , 5 ] Survival before widespread effective ART was typically 1 to 2 years after AIDS-defining illness. (medscape.com)
  • The development of an effective human immunodeficiency virus (HIV) vaccine is a high global priority. (emmes.com)
  • All flu vaccines are effective against the flu. (flutalk.net)
MRNA1
  • I'll be presenting today on some updates on COVID-19 mRNA vaccine effectiveness. (cdc.gov)
Experimental vaccine2
  • This earlier vaccine, called AIDSVAX, was used in combination with another experimental vaccine in a large-scale clinical trial in Thailand involving 16,000 people. (sciencedaily.com)
  • These mice showed a similar immune response to mice given an experimental vaccine for MERS-CoV, a related coronavirus, Barney Graham, director of NIAID's vaccine research center, told Stat News. (livescience.com)